DWP
VRTX icon

Daymark Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Daymark Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Buy
1,193
+416
+54% +$184K 0.01% 440
2026
Q1 		$347K Buy
777
+80
+11% +$37.3K 0.01% 529
2025
Q4 		$316K Sell
697
-2
-0.3% -$862 0.01% 477
2025
Q3 		$274K Buy
699
+247
+55% +$103K 0.01% 505
2025
Q2 		$201K Sell
452
-15
-3% -$6.91K 0.01% 542
2025
Q1 		$226K Buy
+467
New +$218K 0.01% 467
2024
Q4 		– Sell
-804
Closed -$374K – 526
2024
Q3 		$374K Buy
804
+22
+3% +$10.6K 0.02% 386
2024
Q2 		$367K Buy
782
+219
+39% +$95.1K 0.02% 369
2024
Q1 		$235K Buy
+563
New +$238K 0.01% 387

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Daymark Wealth Partners's VRTX Position: Q2 2026 in Review

Daymark Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 54% in Q2 2026, buying an estimated $184K and bringing the position to 1,193 shares worth $593K. The position accounts for 0.01% of the portfolio, ranked #440.

Daymark Wealth Partners first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Daymark Wealth Partners held 1,193 shares of Vertex Pharmaceuticals worth $593K as of Q2 2026.
  • Daymark Wealth Partners bought 416 Vertex Pharmaceuticals shares in Q2 2026, an estimated $184K.
  • Vertex Pharmaceuticals made up 0.01% of Daymark Wealth Partners's portfolio in Q2 2026, its #440 holding.
  • Daymark Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.